VKTX - バイキング・セラピュ―ティクス (Viking Therapeutics Inc.)

VKTXのニュース

   Viking Therapeutics to Participate in Upcoming Investor Conferences  2021/09/02 20:05:00 PR Newswire
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming
   Viking Therapeutics: Remaining Bullish And Sticking To My Plan  2021/08/27 15:52:04 Seeking Alpha
   Viking Therapeutics (VKTX) Investor Presentation - Slideshow  2021/08/13 19:36:01 Seeking Alpha
   Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript  2021/07/29 01:27:09 Seeking Alpha
   Viking Therapeutics shares fall after wider Q2 net loss  2021/07/28 21:00:06 Seeking Alpha
   Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript  2021/07/29 01:27:09 Seeking Alpha
   Viking Therapeutics shares fall after wider Q2 net loss  2021/07/28 21:00:06 Seeking Alpha
   Viking Therapeutics EPS in-line  2021/07/28 20:12:18 Seeking Alpha
   Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021  2021/07/21 20:05:00 PR Newswire
SAN DIEGO, July 21, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for
   Viking Therapeutics shares rise after initiating early-stage VK0214 study  2021/06/24 11:32:19 Seeking Alpha
   Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly  2021/04/06 13:07:55 Benzinga
The following article is sponsored by Actinium Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. As science advances in terms of finding new treatments for unmet medical needs, certain approaches are not appropriate for specific types of patients. For example, when it comes to older patients, often certain treatments can be counterproductive, leaving them vulnerable and without a way to combat the disease. In the biotech world, many are racing to give people solutions and hope for a better future. While we are ages from having prompt answers, companies like Fortress Biotech, Inc. (NASDAQ: FBIO ), Viking Therapeutics (NASDAQ: VKTX ), Onconova Therapeutics (NASDAQ: ONTX ), Fusion Pharmaceuticals Inc (NASDAQ: FUSN ), Gilead Sciences, Inc. (NASDAQ: GILD ) and Bristol-Myers Squibb (NYSE: BMY ), among others, are on the front lines of this race.
   Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update  2021/02/17 21:05:00 PR Newswire
SAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year…
   Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021  2021/02/10 21:05:00 PR Newswire
SAN DIEGO, Feb. 10, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO  2021/01/28 13:03:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Kaleido Biosciences Inc (NASDAQ: KLDO ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Nantkwest Inc (NASDAQ: NK ) Penumbra Inc (NYSE: PEN ) Regulus Therapeutics Inc (NASDAQ: RGLS ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Summit Therapeutics Inc (NASDAQ: SMMT ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Vanda Pharmaceuticals Inc.
   Viking Therapeutics Announces Senior Management Team Appointments  2021/01/06 21:05:00 PR Newswire
SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced two key executive promotions. The company has named…

calendar